Abstract
We present a case of a 42-year old female with the rare diagnosis of a myeloproliferative syndrome harboring both a BCR-ABL transclocation and a JAK2V617F mutation.Initially diagnosed with a CML, the patient underwent treatment with imatinib followed by dasatinib. Despite a major molecular response, the patient developed a thrombocytosis. Molecular analyses revealed a heterozygous JAK2V617F mutation, which was detected retrospectively in the bone marrow at the time of CML diagnosis.This case underlines the complexity of MPS pathogenesis. For the clinician, a JAK2 mutational screening should be performed in CML patients without hematological response in the absence of BCR-ABL.
| Dokumententyp: | Zeitschriftenartikel |
|---|---|
| Publikationsform: | Publisher's Version |
| Fakultät: | Medizin |
| Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
| URN: | urn:nbn:de:bvb:19-epub-24196-3 |
| ISSN: | 2162-3619 |
| Sprache: | Englisch |
| Dokumenten ID: | 24196 |
| Datum der Veröffentlichung auf Open Access LMU: | 18. Mrz. 2015 10:57 |
| Letzte Änderungen: | 04. Nov. 2020 13:05 |

